What is ALT's current stock price?

As of now, ALT is trading at $4.19, with a daily change of +5.81%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

ALT Stock Analysis & IQ Rating | Altimmune

ALT

Altimmune

$4.19

+$0.23 | +5.81%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$7.83

MKT CAP

$439.43M

52W Low

$2.91

VOL

$7.23M

P/E Ratio

N/A

AVG VOL

$5.19M

RSI

47.46

TREND

Sideways

BQ Stock IQ

Login to see Altimmune (ALT) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

ALT Target Price

Login to display

Strengths

ALT Rewards

Upgraded on attractively valued

ALT Rewards

Earnings are forecast to grow

ALT Rewards

Outperform the market

ALT Price Performance

$5.43 (-22.84%)

$4.02 (+4.23%)

$3.63 (+15.43%)

1year

6month

3month

1month

ALT Risk Level

ALT has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Price under $5

High volatilty

Fair

LOW

HIGH

ALT Analysts Opinion

ALT overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

ALT Analysts Opinion

ALT Analysts opinion is negative and it remained unchanged from the past 3 months

ALT Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

85%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

50%

100%

ALT Street Sentiment

ALT Street Sentiment is extremely bullish and have positive views on the near-term outlook

ALT Performance Sentiment

Sentiments overview associated with ALT events and the stock performance.

85%

15%

Positive

Negative

11 out of 13
events present

2 out of 13
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$3.96

Resistance
Price

$3.51

Current Price Range

$5.61

Show methods +

Linked to ALT

IQ

Close Price

Change

VKTX

4.13

32.38

+0.25%

ALT Latest Analysis +

ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH. Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.

Tue Jan 6, 2026

$3.96 | -3.18%

Activity

Momentum

Altimmunes Pemvidutide Earns FDA Breakthrough Status In MASH . (RTTNews) - Altimmune Inc. (ALT) announced that the United States FDA granted Breakthrough Therapy Designation for Pemvidutide its balanced 1:1 glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis.

Tue Jan 6, 2026

$3.96 | -3.18%

Activity

Altimmune GH Research Gyre Therapeutics And Other Big Stocks Moving Higher On Monday. United States stocks were higher with the Dow Jones index gaining more than 500 points on Monday.Shares of ALT) rose sharply during Monday'.s session after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH.Altimmune shares jumped 23.6% to $4.34 on Monday.Here are some other big stocks recording gains in today’.s session.GHRS) gained 33.8% to $17.72. The United States Food and Dru

Mon Jan 5, 2026

$4.09 | +16.52%

Activity

Momentum

Why Altimmune Is Rising In Pre-market? . (RTTNews) - Altimmune (ALT) announced the FDA has granted Breakthrough Therapy Designation for pemvidutide a 1:1 glucagon/GLP-1 dual receptor agonist for the treatment of patients with metabolic dysfunction-associated steatohepatitis.

Mon Jan 5, 2026

$4.09 | +16.52%

Activity

Altimmune Stock Falls 20% After Pemvidutide 48-Week Trial Update . (RTTNews) - Altimmune Inc. (ALT) shares fell 20.40% closing at $4.02 down $1.03 after the company announced 48-week results from its Phase 2b IMPACT trial evaluating pemvidutide in patients with MASH.

Fri Dec 19, 2025

$3.90 | -22.77%

Momentum

Altimmunes MASH Drug Shows Durable Liver Weight Loss Gains At 48 Weeks. ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide. Patients had (MASH) at 48 weeks.MASH is a liver disease marked by excess liver fat (steatosis) alongside inflammation and liver cell damage.Topline 48-week data from the IMPACT trial showed that treatment with pemvidutide achieved statistically significant improvements across treatment arms in key noninvasive tests including Enhanced Liver

Fri Dec 19, 2025

$3.90 | -22.77%

Activity

Potential

Altimmune stock tumbles after MASH drug trial data.

Fri Dec 19, 2025

$3.90 | -22.77%

Momentum

Altimmunes Pemvidutide Achieves Key Fibrosis And Weight Loss Endpoints At 48 Weeks . (RTTNews) - Altimmune Inc. (ALT) announced that its investigational dual glucagon/GLP-1 receptor agonist pemvidutide achieved statistically significant improvements in non-invasive markers of liver fibrosis and sustained weight loss at 48 weeks in Phase 2b IMPACT trial in patie

Fri Dec 19, 2025

$3.90 | -22.77%

Activity

Altimmune Reports Positive 48-Week Phase 2b Data For Pemvidutide In MASH . (RTTNews) - Altimmune Inc. (ALT) on Friday reported positive topline results from the IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks.

Fri Dec 19, 2025

$3.90 | -22.77%

Activity

FAQ About ALT Stock Insights

What is ALT current stock price?

What are ALT stock strengths?

What is ALT Risk Level?

What is ALT market cap and volume?

What is ALT current Stock IQ?

Should I buy ALT stock right now?

Is ALT a Strong Buy right now?

What does a 'Strong Buy' rating mean for ALT?

What does a 'Strong Sell' rating mean for ALT?

What factors influence ALT's Stock IQ?

Explore our ALT Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored ALT Stock Strategies
Effective Risk Management

FIND US ON

Receive our ALT Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

ALT

Altimmune

Current Price

$4.19

+$0.23 | +5.81%

52W High

$7.83

MKT CAP

$439.43M

52W Low

$2.91

VOL

$7.23M

P/E Ratio

N/A

AVG VOL

$5.19M

RSI

47.46

TREND

Sideways

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

ALT Rewards

Upgraded on attractively valued

ALT Rewards

Earnings are forecast to grow

ALT Rewards

Outperform the market

Linked to ALT

Symbol

IQ

Close

Change

VKTX

4.13

32.38

+0.25%

ALT Price Performance

$5.43 (-22.84%)

$4.02 (+4.23%)

$3.63 (+15.43%)

1year

6month

3month

1month

ALT Analysts Opinion

ALT Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

ALT Analysts Opinion

ALT Analysts opinion is negative and it remained unchanged from the past 3 months

ALT Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

85%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

50%

100%

ALT Street Sentiment

ALT Street Sentiment is extremely bullish and have positive views on the near-term outlook

ALT Risk Level

ALT has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Price under $5

High volatilty

Fair

LOW

HIGH

ALT Performance Sentiment

Sentiments overview associated with ALT events and the stock performance.

85%

15%

Positive

Negative

11 out of 13
events present

2 out of 13
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$3.96

Resistance
Price

$3.51

Current Price Range

$5.61

Show methods +

ALT Stock IQ

Login to unlock Altimmune (ALT) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

ALT Latest Analysis

ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH. Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.

Tue Jan 6, 2026

$3.96 | -3.18%

Activity

Momentum

Altimmunes Pemvidutide Earns FDA Breakthrough Status In MASH . (RTTNews) - Altimmune Inc. (ALT) announced that the United States FDA granted Breakthrough Therapy Designation for Pemvidutide its balanced 1:1 glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis.

Tue Jan 6, 2026

$3.96 | -3.18%

Activity

Altimmune GH Research Gyre Therapeutics And Other Big Stocks Moving Higher On Monday. United States stocks were higher with the Dow Jones index gaining more than 500 points on Monday.Shares of ALT) rose sharply during Monday'.s session after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH.Altimmune shares jumped 23.6% to $4.34 on Monday.Here are some other big stocks recording gains in today’.s session.GHRS) gained 33.8% to $17.72. The United States Food and Dru

Mon Jan 5, 2026

$4.09 | +16.52%

Activity

Momentum

Why Altimmune Is Rising In Pre-market? . (RTTNews) - Altimmune (ALT) announced the FDA has granted Breakthrough Therapy Designation for pemvidutide a 1:1 glucagon/GLP-1 dual receptor agonist for the treatment of patients with metabolic dysfunction-associated steatohepatitis.

Mon Jan 5, 2026

$4.09 | +16.52%

Activity

Altimmune Stock Falls 20% After Pemvidutide 48-Week Trial Update . (RTTNews) - Altimmune Inc. (ALT) shares fell 20.40% closing at $4.02 down $1.03 after the company announced 48-week results from its Phase 2b IMPACT trial evaluating pemvidutide in patients with MASH.

Fri Dec 19, 2025

$3.90 | -22.77%

Momentum

Altimmunes MASH Drug Shows Durable Liver Weight Loss Gains At 48 Weeks. ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide. Patients had (MASH) at 48 weeks.MASH is a liver disease marked by excess liver fat (steatosis) alongside inflammation and liver cell damage.Topline 48-week data from the IMPACT trial showed that treatment with pemvidutide achieved statistically significant improvements across treatment arms in key noninvasive tests including Enhanced Liver

Fri Dec 19, 2025

$3.90 | -22.77%

Activity

Potential

Altimmune stock tumbles after MASH drug trial data.

Fri Dec 19, 2025

$3.90 | -22.77%

Momentum

Altimmunes Pemvidutide Achieves Key Fibrosis And Weight Loss Endpoints At 48 Weeks . (RTTNews) - Altimmune Inc. (ALT) announced that its investigational dual glucagon/GLP-1 receptor agonist pemvidutide achieved statistically significant improvements in non-invasive markers of liver fibrosis and sustained weight loss at 48 weeks in Phase 2b IMPACT trial in patie

Fri Dec 19, 2025

$3.90 | -22.77%

Activity

Altimmune Reports Positive 48-Week Phase 2b Data For Pemvidutide In MASH . (RTTNews) - Altimmune Inc. (ALT) on Friday reported positive topline results from the IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks.

Fri Dec 19, 2025

$3.90 | -22.77%

Activity

Discover ALT Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of ALT. We're here to help you make informed investment decisions today.

FIND US ON

Receive our ALT Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

ALT Stock trends

ALT Stock performance

ALT Stock analysis

ALT investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing ALT

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing ALT

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

ALT Stock Analysis & IQ Rating | Altimmune

BQ Stock IQ

ALT Target Price

ALT Risk Level

ALT Analysts Opinion

ALT Street Sentiment

ALT Performance Sentiment

Technical Price Levels

Explore our ALT Stock insights

Receive our ALT Daily Alerts

ALT Street Sentiment

ALT Risk Level

Technical Price Levels

Discover ALT Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of ALT. We're here to help you make informed investment decisions today.

Receive our ALT Daily Alerts

ALT Alerts